journal
MENU ▼
Read by QxMD icon Read
search

Gynecologic Oncology Research and Practice

journal
https://www.readbyqxmd.com/read/29158911/a-retrospective-evaluation-of-activity-of-gemcitabine-platinum-regimens-in-the-treatment-of-recurrent-ovarian-cancer
#1
Tran N Le, Rachel E Harvey, Christine K Kim, Jubilee Brown, Robert L Coleman, Judith A Smith
Background: While many of these agents have been compared in prospective clinical trials, the gemcitabine/platinumbased regimens have not been compared in a prospective, randomized clinical trial. While bothgemcitabine/carboplatin and gemcitabine/cisplatin have a similar ORR in separate clinical trials, the tworegimens have never been directly been compared. With overlapping dose-limiting toxicity of thrombocytopenia, the gemcitabine/carboplatin regimen has been challenging to employ in the clinical setting in previously treated ovarian cancer patients and is often associated with treatment delays and/or dose reductions...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/29093822/ezh2-inhibition-in-arid1a-mutated-clear-cell-and-endometrioid-ovarian-and-endometrioid-endometrial-cancers
#2
REVIEW
Jill K Alldredge, Ramez N Eskander
Clear cell carcinoma and endometrioid adenocarcinoma are histologic subtypes of ovarian and uterine cancer that demonstrate unique clinical behavior but share common underlying genomic aberrations and oncogenic pathways. ARID1A mutations are more frequently identified in these tumors, in comparison to other gynecologic histologies, and loss of ARID1A tumor suppressor function is thought to be an essential component of carcinogenic transformation. Several therapeutic targets in ARID1A mutated cancers are in development, including EZH2 inhibitors...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/29075505/assessment-of-drug-therapy-problems-among-patients-with-cervical-cancer-at-kenyatta-national-hospital-kenya
#3
Amsalu Degu, Peter Njogu, Irene Weru, Peter Karimi
BACKGROUND: Although cervical cancer is preventable, it is still the second leading cause of cancer deaths among women in the world. Further, it is estimated that around 5-10% of hospital admissions are due to drug related problems (DRPs), of which 50% are avoidable. In cancer therapy, there is an immense potential for DRPs due to the high toxicity of most chemotherapeutic regimens. Hence, this study sought to assess DRPs among patients with cervical cancer at Kenyatta National Hospital (KNH)...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28989727/preparation-in-the-business-and-practice-of-medicine-perspectives-from-recent-gynecologic-oncology-graduates-and-program-directors
#4
Matthew Schlumbrecht, John Siemon, Guillermo Morales, Marilyn Huang, Brian Slomovitz
BACKGROUND: Preparation in the business of medicine is reported to be poor across a number of specialties. No data exist about such preparation in gynecologic oncology training programs. Our objectives were to evaluate current time dedicated to these initiatives, report recent graduate perceptions about personal preparedness, and assess areas where improvements in training can occur. METHODS: Two separate surveys were created and distributed, one to 183 Society of Gynecologic Oncology candidate members and the other to 48 gynecologic oncology fellowship program directors...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28904804/bringing-new-medicines-to-women-with-epithelial-ovarian-cancer-what-is-the-unmet-medical-need
#5
REVIEW
Thomas J Herzog, Bradley J Monk
BACKGROUND: Therapy for advanced epithelial ovarian cancer (OC) includes first line platinum/taxane-containing chemotherapy and re-treatment with platinum-containing regimens for disease recurrence in patients likely to respond again. Single-agent, non-platinum, cytotoxic agents are commonly used to treat patients resistant to platinum retreatment, but these agents are associated with dose-limiting toxicities and response rates below 20%. MAIN BODY: Recent advances have led to novel targeted treatments for recurrent OC that offer opportunities to improve response rates and prolong progression-free intervals...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28852531/transversus-abdominis-plane-block-with-liposomal-bupivacaine-compared-to-oral-opioids-alone-for-acute-postoperative-pain-after-laparoscopic-hysterectomy-for-early-endometrial-cancer-a-cost-effectiveness-analysis
#6
Brandon-Luke L Seagle, Emily S Miller, Anna E Strohl, Anna Hoekstra, Shohreh Shahabi
BACKGROUND: To determine the cost-effectiveness of transversus abdominis plane block with liposomal bupivacaine (TAP) compared to oral opioids alone for acute postoperative pain after laparoscopic hysterectomy for early endometrial cancer. METHODS: A cost-effectiveness analysis using a decision tree structure with a 30.5 day time-horizon was used to calculate incremental cost-effectiveness ratio (ICER) values per quality-adjusted life-year (QALY). Base-case costs, probabilities, and QALY values were identified from recently published all-payer national database studies, 2017 Medicare fee-schedules, randomized trials, institutional case series, or assumed, when published values were not available...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28852530/multidisciplinary-approach-to-manage-antenatally-suspected-placenta-percreta-updated-algorithm-and-patient-outcomes
#7
Paula S Lee, Samantha Kempner, Michael Miller, Jennifer Dominguez, Chad Grotegut, Jessie Ehrisman, Rebecca Previs, Laura J Havrilesky, Gloria Broadwater, Sarah C Ellestad, Angeles Alvarez Secord
BACKGROUND: Due to the significant morbidity and mortality associated with placenta percreta, alternative management options are needed. Beginning in 2005, our institution implemented a multidisciplinary strategy to patients with suspected placenta percreta. The purpose of this study is to present our current strategy, maternal morbidity and outcomes of patients treated by our approach. METHODS: From 2005 to 2014, a retrospective cohort study of patients with suspected placenta percreta at an academic tertiary care institution was performed...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28725449/therapeutic-options-for-treatment-of-human-papillomavirus-associated-cancers-novel-immunologic-vaccines-adxs11-001
#8
REVIEW
Brett Miles, Howard P Safran, Bradley J Monk
Survival of patients with advanced, recurrent, or metastatic human papillomavirus (HPV)-associated cancer is suboptimal despite the availability of various treatment modalities. The recently developed bacterial vector Listeria monocytogenes (Lm) activates innate and adaptive immune responses and is expected to offer immunologic advantages. Axalimogene filolisbac (AXAL or ADXS11-001) is a novel immunotherapeutic based on the live, irreversibly attenuated Lm fused to the nonhemolytic fragment of listeriolysin O (Lm-LLO) and secretes the Lm-LLO-HPV E7 fusion protein targeting HPV-positive tumors...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28588899/mechanistic-insights-into-adxs11-001-human-papillomavirus-associated-cancer-immunotherapy
#9
REVIEW
Brett A Miles, Bradley J Monk, Howard P Safran
Immune responses to the facultative intracellular bacterium Listeria monocytogenes (Lm) are robust and well characterized. Utilized for decades as a model of host-disease immunology, Lm is well suited for use as an immunotherapeutic bacterial vector for the delivery of foreign antigen. Genetic modification of Lm has been undertaken to create an attenuated organism that is deficient in its master transcriptional regulator, protein-related factor A, and incorporates a truncated, nonhemolytic version of the listeriolysin O (LLO) molecule to ensure its adjuvant properties while also preventing escape of the live organism from the phagolysosome...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28352472/erratum-to-options-in-human-papillomavirus-hpv-detection-for-cervical-cancer-screening-comparison-between-full-genotyping-and-a-rapid-qualitative-hpv-dna-assay-in-ghana
#10
Dorcas Obiri-Yeboah, Yaw Adu-Sarkodie, Florencia Djigma, Kafui Akakpo, Ebenezer Aniakwa-Bonsu, Daniel Amoako-Sakyi, Jacques Simpore, Philippe Mayaud
[This corrects the article DOI: 10.1186/s40661-017-0041-1.].
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28344818/will-bevacizumab-biosimilars-impact-the-value-of-systemic-therapy-in-gynecologic-cancers
#11
REVIEW
Bradley J Monk, Warner K Huh, Julie Ann Rosenberg, Ira Jacobs
OBJECTIVE: Bevacizumab is an important component in the treatment of various cancers, and despite guidelines recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis inhibitors is limited. Biosimilars are large, structurally complex molecules that are intended to be highly similar to, and treat the same condition(s) as, an existing licensed or approved (reference) biologic, with no clinically meaningful differences in purity, potency and safety...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28286660/preference-of-elderly-patients-to-oral-or-intravenous-chemotherapy-in-heavily-pre-treated-recurrent-ovarian-cancer-final-results-of-a-prospective-multicenter-trial
#12
Radoslav Chekerov, Philipp Harter, Stefan Fuxius, Lars Christian Hanker, Linn Woelber, Lothar Müller, Peter Klare, Wolfgang Abenhardt, Yoana Nedkova, Isil Yalcinkaya, Georg Heinrich, Harald Sommer, Sven Mahner, Pauline Wimberger, Dominique Koensgen-Mustea, Rolf Richter, Gülten Oskay-Oezcelik, Jalid Sehouli
BACKGROUND: Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as oral (p.o.) or intravenous (i.v.) application. The aim of this innovative trial was to evaluate the preference of elderly patients (≥65 years) for p.o. or i.v. chemotherapy focusing compliance, outcome, toxicities, and geriatric aspects as secondary endpoints. METHODS: Patients with ROC had the free choice between treosulfan i...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28270915/options-in-human-papillomavirus-hpv-detection-for-cervical-cancer-screening-comparison-between-full-genotyping-and-a-rapid-qualitative-hpv-dna-assay-in-ghana
#13
Dorcas Obiri-Yeboah, Yaw Adu-Sarkodie, Florencia Djigma, Kafui Akakpo, Ebenezer Aniakwa-Bonsu, Daniel Amoako-Sakyi, Simpore Jacques, Philippe Mayaud
BACKGROUND: Modern cervical cancer screening increasingly relies on the use of molecular techniques detecting high-risk oncogenic human papillomavirus (hr-HPV). A major challenge for developing countries like Ghana has been the unavailability and costs of HPV DNA-based testing. This study compares the performance of careHPV, a semi-rapid and affordable qualitative detection assay for 14 hr-HPV genotypes, with HPV genotyping, for the detection of cytological cervical squamous intraepithelial lesions (SIL)...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28250960/homologous-recombination-deficiency-hrd-testing-in-ovarian-cancer-clinical-practice-a-review-of-the-literature
#14
REVIEW
Melissa K Frey, Bhavana Pothuri
Until recently our knowledge of a genetic contribution to ovarian cancer focused almost exclusively on mutations in the BRCA1/2 genes. However, through germline and tumor sequencing an understanding of the larger phenomenon of homologous recombination deficiency (HRD) has emerged. HRD impairs normal DNA damage repair which results in loss or duplication of chromosomal regions, termed genomic loss of heterozygosity (LOH). The list of inherited mutations associated with ovarian cancer continues to grow with the literature currently suggesting that up to one in four cases will have germline mutations, the majority of which result in HRD...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28174665/metastatic-small-cell-neuroendocrine-carcinoma-of-the-cervix-treated-with-the-pd-1-inhibitor-nivolumab-a-case-report
#15
Sarah E Paraghamian, Teresa C Longoria, Ramez N Eskander
BACKGROUND: Nivolumab is an immune checkpoint inhibitor specific for the programmed death 1 (PD-1) receptor that has led to clinical responses in many cancer types. Identifying biomarkers predictive of response to PD-1 blockade is an area of active investigation. CASE PRESENTATION: We present a patient with recurrent, metastatic, PD-L1-negative small cell neuroendocrine carcinoma of the cervix (SCNEC) who experienced a complete response to nivolumab. Though nivolumab was discontinued over 4 months ago due to treatment-related adverse events, she continues to have no evidence of disease...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28138393/clinical-features-and-treatment-of-vulvar-merkel-cell-carcinoma-a-systematic-review
#16
REVIEW
Austin Huy Nguyen, Ahmed I Tahseen, Adam M Vaudreuil, Gabriel C Caponetti, Christopher J Huerter
BACKGROUND: Merkel cell carcinoma is a rare and aggressive neoplasm originating from mechanoreceptor Merkel cells of the stratum basale of the epidermis. Cases affecting the vulva are exceedingly rare, with the currently available literature primarily in case report form. BODY: Systematic review of the PubMed database returned 17 cases of Merkel cell carcinoma affecting the vulva. Patients presented at a mean age of 59.6 years with a firm, mobile vulvar mass. Symptoms of pain, erythema, pruritus, edema, and ulceration have been reported...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28116108/disparities-in-the-surgical-staging-of-high-grade-endometrial-cancer-in-the-united-states
#17
Jonathan R Foote, Stephanie Gaillard, Gloria Broadwater, Julie A Sosa, Brittany Davidson, Mohamed A Adam, Angeles Alvarez Secord, Monica B Jones, Junzo Chino, Laura J Havrilesky
BACKGROUND: The National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO) recommend lymph node sampling (LNS) as a key component in the surgical staging of high-grade endometrial cancer. Our goal was to examine surgical staging patterns for high-grade endometrial cancer in the United States. METHODS: The National Cancer Data Base (NCDB) was searched for patients who underwent surgery for serous, clear cell, or grade 3 endometrioid endometrial cancer...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28685778/fifth-annual-workshop-of-cytoreductive-surgery-for-advanced-ovarian-cancer-and-peritoneal-surface-malignancies
#18
Krishnansu S Tewari
The Fifth Annual Advanced Course in Cytoreductive Surgery for Ovarian Cancer and Peritoneal Surface Malignancies was held at and sponsored by the Division of Gynecologic Oncology at the the University of California, Irvine on Friday and Saturday, October 9-10, 2015. The workshop was comprised of didactic modules, historical treatise, an impassioned tribute, a cadaver laboratory, and heated intraperitoneal chemotherapy demonstration. This was a not-for-profit workshop, and registration fees were used to support course faculty travel to U...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27999680/new-classification-of-endometrial-cancers-the-development-and-potential-applications-of-genomic-based-classification-in-research-and-clinical-care
#19
REVIEW
A Talhouk, J N McAlpine
Endometrial carcinoma (EC) is the fourth most common cancer in women in the developed world. Classification of ECs by histomorphologic criteria has limited reproducibility and better tools are needed to distinguish these tumors and enable a subtype-specific approach to research and clinical care. Based on the Cancer Genome Atlas, two research teams have developed pragmatic molecular classifiers that identify four prognostically distinct molecular subgroups. These methods can be applied to diagnostic specimens (e...
2016: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/27980799/analysis-of-in-vitro-chemoresponse-assays-in-endometrioid-endometrial-adenocarcinoma-an-observational-ancillary-analysis
#20
Brittany A Davidson, Jonathan Foote, Stacey L Brower, Chunqiao Tian, Laura J Havrilesky, Angeles Alvarez Secord
BACKGROUND: Chemotherapy plays a role in the treatment of endometrioid endometrial cancer (EEC); however, tumor grade may affect response. Our objective was to evaluate associations between tumor grade and in vitro chemoresponse. METHODS: We conducted an analysis of primary tumor samples from women with EEC undergoing in vitro chemoresponse testing. Results were classified as sensitive (S), intermediate (I), or resistant (R) to each drug tested. Correlations between tumor grade and response were examined...
2016: Gynecologic Oncology Research and Practice
journal
journal
53287
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"